

DAFTAR PUSTAKA

- Almansour, N. M. (2022). Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. *Frontiers in Molecular Biosciences*, 9. <https://doi.org/10.3389/fmolb.2022.836417>
- Amanvermez, R., & Tosun, M. (2016). An Update on Ovarian Aging and Ovarian Reserve Tests. *International Journal of Fertility & Sterility*, 9(4), 411–415. <https://doi.org/10.22074/ijfs.2015.4591>
- Asaoka, M., Gandhi, S., Ishikawa, T., & Takabe, K. (2020). Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. *Breast Cancer: Basic and Clinical Research*, 14, 117822342098037. <https://doi.org/10.1177/1178223420980377>
- Ayuandari, S., Dewanto, A., Oktasari, R., Rahmawati, N. R., Alma, N. A., Hamurajib, K. C., & Mulatsih, S. (2022a). Anti-Mullerian hormone and puberty development in girls and adolescents who underwent cancer treatment. *Archives of Gynecology and Obstetrics*, 305(6), 1581–1586. <https://doi.org/10.1007/s00404-021-06364-5>
- Ayuandari, S., Dewanto, A., Oktasari, R., Rahmawati, N. R., Alma, N. A., Hamurajib, K. C., & Mulatsih, S. (2022b). Anti-Mullerian hormone and puberty development in girls and adolescents who underwent cancer treatment. *Archives of Gynecology and Obstetrics*, 305(6), 1581–1586. <https://doi.org/10.1007/s00404-021-06364-5>
- Bala, J., Seth, S., Dhankhar, R., & Ghalaut, V. S. (2016). Chemotherapy: Impact on anti-müllerian hormone levels in breast carcinoma. *Journal of Clinical and Diagnostic Research*, 10(2), BC19–BC21. <https://doi.org/10.7860/JCDR/2016/15933.7328>
- Bedoschi, G., Navarro, P. A., & Oktay, K. (2016a). Chemotherapy-induced damage to ovary: mechanisms and clinical impact. *Future Oncology*, 12(20), 2333–2344. <https://doi.org/10.2217/fon-2016-0176>
- Bedoschi, G., Navarro, P. A., & Oktay, K. (2016b). Chemotherapy-induced damage to ovary: mechanisms and clinical impact. *Future Oncology*, 12(20), 2333–2344. <https://doi.org/10.2217/fon-2016-0176>
- Bitzer, J., & Mahmood, T. A. (Eds.). (2024). *Textbook of Contraception, Sexual and Reproductive Health*. Cambridge University Press. <https://doi.org/10.1017/9781108961097>
- Bjørn, M., Brendstrup, C., Karlsen, S., & Carlsen, J. E. (1998). Consecutive screening and enrollment in clinical trials: The way to representative patient samples? *Journal of Cardiac Failure*, 4(3), 225–230. [https://doi.org/10.1016/S1071-9164\(98\)80009-2](https://doi.org/10.1016/S1071-9164(98)80009-2)
- Blumenfeld, Z. (2012). Chemotherapy and fertility. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 26(3), 379–390. <https://doi.org/10.1016/j.bpobgyn.2011.11.008>

- Bogdanova, N., Helbig, S., & Dörk, T. (2013). Hereditary breast cancer: ever more pieces to the polygenic puzzle. *Hereditary Cancer in Clinical Practice*, 11(1), 12. <https://doi.org/10.1186/1897-4287-11-12>
- Carr, C., Ng, J., & Wigmore, T. (2008). The side effects of chemotherapeutic agents. *Current Anaesthesia & Critical Care*, 19(2), 70–79. <https://doi.org/10.1016/j.cacc.2008.01.004>
- Chew, H. K. (2001). Adjuvant therapy for breast cancer: who should get what? *The Western Journal of Medicine*, 174(4), 284–287. <https://doi.org/10.1136/ewjm.174.4.284>
- Chien, T.-J. (2021). A review of the endocrine resistance in hormone-positive breast cancer. *American Journal of Cancer Research*, 11(8), 3813–3831.
- Cohen, J., Chabbert-Buffet, N., & Darai, E. (2015). Diminished ovarian reserve, premature ovarian failure, poor ovarian responder—a plea for universal definitions. *Journal of Assisted Reproduction and Genetics*, 32(12), 1709–1712. <https://doi.org/10.1007/s10815-015-0595-y>
- Coombes, R. C., Bliss, J. M., Wils, J., Morvan, F., Espié, M., Amadori, D., Gambrosier, P., Richards, M., Aapro, M., Villar-Grimalt, A., McArdle, C., Pérez-López, F. R., Vassilopoulos, P., Ferreira, E. P., Chilvers, C. E., Coombes, G., Woods, E. M., & Marty, M. (1996). Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. *Journal of Clinical Oncology*, 14(1), 35–45. <https://doi.org/10.1200/JCO.1996.14.1.35>
- Coughlin, S. S. (2019). *Epidemiology of Breast Cancer in Women* (pp. 9–29). https://doi.org/10.1007/978-3-030-20301-6_2
- Crowne, E., Gleeson, H., Benghiat, H., Sanghera, P., & Toogood, A. (2015). Effect of cancer treatment on hypothalamic–pituitary function. *The Lancet Diabetes & Endocrinology*, 3(7), 568–576. [https://doi.org/10.1016/S2213-8587\(15\)00008-X](https://doi.org/10.1016/S2213-8587(15)00008-X)
- Dahlan, S. M. (2016). *Statistik untuk Kedokteran dan Kesehatan*. Salemba Medika.
- D’Avila, Â. M., Capp, E., & Corleta, H. von E. (2017). Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*, 39(04), 162–168. <https://doi.org/10.1055/s-0037-1601438>
- de Ciantis, M., Faure, C., Heudel, P.-E., Tredan, O., & Rousset-Jablonski, C. (2018). Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients. *Journal of Gynecology Obstetrics and Human Reproduction*, 47(6), 261–264. <https://doi.org/10.1016/j.jogoh.2018.03.002>
- Durrieu, G., Rigal, M., Bugat, R., & Lapeyre-Mestre, M. (2004). Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women. *Fundamental & Clinical Pharmacology*, 18(5), 573–579. <https://doi.org/10.1111/j.1472-8206.2004.00267.x>
- El-Serafi, I., & Steele, S. (2024). Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics.

- Advances in Pharmacological and Pharmaceutical Sciences*, 2024(1).
<https://doi.org/10.1155/2024/4862706>
- Emens, L. A., & Jaffee, E. M. (2005). Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy. *Cancer Research*, 65(18), 8059–8064.
<https://doi.org/10.1158/0008-5472.CAN-05-1797>
- Fabiani, C., Ferrante, M. G., Meneghini, C., Licata, E., Paciotti, G., Gallo, M., Schiavi, M., Spina, V., Guarino, A., Caserta, D., & Rago, R. (2022). Female fertility preservation: Impact of cancer on ovarian function and oocyte quality. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics*, 156(1), 166–171.
<https://doi.org/10.1002/ijgo.13702>
- Frausto, V. M. R., Ortega, L. C., Chapas, J. M. de la R., González, M. A. H., Sabanero, G. B., & Rocha, M. G. (2020). Correlation between stress, cortisol levels and coping strategies in cancer patients undergoing treatment. *Enfermería Global*, 19(4), 196–219. <https://doi.org/10.6018/eglobal.410951>
- Freedland, S. J., & Abrahamsson, P.-A. (2021). Androgen deprivation therapy and side effects. *Asian Journal of Andrology*, 23(1), 3–10.
https://doi.org/10.4103/aja.aja_22_20
- Freeman, E. W., Sammel, M. D., Lin, H., & Gracia, C. R. (2012). Anti-Müllerian Hormone as a Predictor of Time to Menopause in Late Reproductive Age Women. *The Journal of Clinical Endocrinology & Metabolism*, 97(5), 1673–1680. <https://doi.org/10.1210/jc.2011-3032>
- Gracia, C. R., Sammel, M. D., Freeman, E., Prewitt, M., Carlson, C., Ray, A., Vance, A., & Ginsberg, J. P. (2012). Impact of cancer therapies on ovarian reserve. *Fertility and Sterility*, 97(1), 134–140.e1.
<https://doi.org/10.1016/j.fertnstert.2011.10.040>
- Guo, Y., Xue, L., Tang, W., Xiong, J., Chen, D., Dai, Y., Wu, C., Wei, S., Dai, J., Wu, M., & Wang, S. (2024). Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage. *Human Reproduction Update*, 30(5), 614–647.
<https://doi.org/10.1093/humupd/dmae020>
- Han, S., & Tomori, C. (2021). *The Routledge Handbook of Anthropology and Reproduction*. Routledge. <https://doi.org/10.4324/9781003216452>
- Harlow, S. D., Lin, X., & Ho, M. J. (2000). Analysis of menstrual diary data across the reproductive life span Applicability of the bipartite model approach and the importance of within-woman variance. *Journal of Clinical Epidemiology*, 53(7), 722–733. [https://doi.org/10.1016/S0895-4356\(99\)00202-4](https://doi.org/10.1016/S0895-4356(99)00202-4)
- Haukoos, J. S., & Lewis, R. J. (2015). The Propensity Score. *JAMA*, 314(15), 1637.
<https://doi.org/10.1001/jama.2015.13480>
- Himpe, J., Lammerant, S., Van den Bergh, L., Lapeire, L., & De Roo, C. (2023). The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review. *Life*, 13(5), 1209.
<https://doi.org/10.3390/life13051209>
- Holsh, J. E., Bass, A. N., & Lord, M. (2023). *Physiology, Ovulation*. StatPearls Publishing.

- Huang, Y., Huang, X., Huang, X., Lin, S., Luo, S., Gu, D., Weng, X., & Xu, X. (2023). Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer. *Human Reproduction*, 38(6), 1099–1110. <https://doi.org/10.1093/humrep/dead073>
- Hyltdgaard, J., Bor, P., Ingerslev, H. J., & Tørring, N. (2015). Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. *Reproductive Biology and Endocrinology*, 13(1), 107. <https://doi.org/10.1186/s12958-015-0101-5>
- International Agency for Research on Cancer. (2020). *GLOBOCAN 2020*. <https://gco.iarc.fr/today/fact-sheets-cancers>
- Jeppesen, J. V., Anderson, R. A., Kelsey, T. W., Christiansen, S. L., Kristensen, S. G., Jayaprakasan, K., Raine-Fenning, N., Campbell, B. K., & Yding Andersen, C. (2013). Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. *Molecular Human Reproduction*, 19(8), 519–527. <https://doi.org/10.1093/molehr/gat024>
- Jirge, P. (2016a). Poor ovarian reserve. *Journal of Human Reproductive Sciences*, 9(2), 63. <https://doi.org/10.4103/0974-1208.183514>
- Jirge, P. (2016b). Poor ovarian reserve. *Journal of Human Reproductive Sciences*, 9(2), 63. <https://doi.org/10.4103/0974-1208.183514>
- Kalli, S., Semine, A., Cohen, S., Naber, S. P., Makim, S. S., & Bahl, M. (2018). American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. *RadioGraphics*, 38(7), 1921–1933. <https://doi.org/10.1148/rg.2018180056>
- Kitano, A., Shimizu, C., Yamauchi, H., Akitani, F., Shiota, K., Miyoshi, Y., & Ohde, S. (2019). Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists. *ESMO Open*, 4(2), e000459. <https://doi.org/10.1136/esmoopen-2018-000459>
- Koh, J., & Kim, M. J. (2019). Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. *Korean J Radiol*, 20(1), 69–82. <https://doi.org/10.3348/kjr.2018.0231>
- La Marca, A., Grisendi, V., & Griesinger, G. (2013). How Much Does AMH Really Vary in Normal Women? *International Journal of Endocrinology*, 2013, 1–8. <https://doi.org/10.1155/2013/959487>
- La Marca, A., & Volpe, A. (2006). Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? *Clinical Endocrinology*, 64(6), 603–610. <https://doi.org/10.1111/j.1365-2265.2006.02533.x>
- Leonard, R. C. F., Adamson, D. J. A., Bertelli, G., Mansi, J., Yellowlees, A., Dunlop, J., Thomas, G. A., Coleman, R. E., & Anderson, R. A. (2017). GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. *Annals of Oncology*, 28(8), 1811–1816. <https://doi.org/10.1093/annonc/mdx184>
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification,

- Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers*, 4287. <https://doi.org/10.3390/cancers13174287>
- Maajani, K., Jalali, A., Alipour, S., Khodadost, M., Tohidinik, H. R., & Yazdani, K. (2019). The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis. *Clinical Breast Cancer*, 19(3), 165–177. <https://doi.org/10.1016/j.clbc.2019.01.006>
- Maltaris, T., Weigel, M., Mueller, A., Schmidt, M., Seufert, R., Fischl, F., Koelbl, H., & Dittrich, R. (2008). Cancer and fertility preservation: fertility preservation in breast cancer patients. *Breast Cancer Research*, 10(2), 206. <https://doi.org/10.1186/bcr1991>
- Man, L., Guahmich, N., Vyas, N., Tsai, S., Arazi, L., Lilienthal, D., Schattman, G., Rosenwaks, Z., & James, D. (2022). Ovarian Reserve Disorders, Can We Prevent Them? A Review. *International Journal of Molecular Sciences*, 23, 15426. <https://doi.org/10.3390/ijms232315426>
- Masood, S. (2016). Neoadjuvant chemotherapy in breast cancers. *Women's Health*, 12(5), 480–491. <https://doi.org/10.1177/1745505716677139>
- McCollam, S., Shipman, C., Bubalo, J., & Krieg, S. (2019). Preventing Chemotherapy-Induced Infertility in Female Patients. *Journal of Hematology Oncology Pharmacy*, 9(4), 192–198.
- Meng, K., Tian, W., Zhou, M., Chen, H., & Deng, Y. (2013). Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels. *World Journal of Surgical Oncology*, 11(1), 101. <https://doi.org/10.1186/1477-7819-11-101>
- Moolhuijsen, L. M. E., & Visser, J. A. (2020). Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. *The Journal of Clinical Endocrinology & Metabolism*, 105(11), 3361–3373. <https://doi.org/10.1210/clinem/dgaa513>
- Mulatsih, S., Ayuandari, S., Rahmawati, N. R., Oktasari, R., & Dewanto, A. (2023). Cumulative cyclophosphamide dose and serum anti-Mullerian hormone levels in adolescent cancer survivors in Indonesia. *Paediatrica Indonesiana*, 63(5), 376–382. <https://doi.org/10.14238/pi63.5.2023.376-82>
- Munro, M. G., Critchley, H. O. D., & Fraser, I. S. (2018). The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *International Journal of Gynecology & Obstetrics*, 143(3), 393–408. <https://doi.org/10.1002/ijgo.12666>
- NCCN. (2023). *National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer*.
- NICE Guidelines. (2018). *Heavy menstrual bleeding: assessment and management*.
- Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018). Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*, 36(19), 1994–2001. <https://doi.org/10.1200/JCO.2018.78.1914>

- Oktem, O., & Oktay, K. (2007). Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. *Cancer*, *110*(10), 2222–2229. <https://doi.org/10.1002/cncr.23071>
- Olsson, H. L., & Olsson, M. L. (2020). The Menstrual Cycle and Risk of Breast Cancer: A Review. *Frontiers in Oncology*, *10*. <https://doi.org/10.3389/fonc.2020.00021>
- Peacock, K., & Ketvertis, K. M. (2023). *Menopause*. StatPearls Publishing.
- Penzias, A., Azziz, R., Bendikson, K., Falcone, T., Hansen, K., Hill, M., Hurd, W., Jindal, S., Kalra, S., Mersereau, J., Racowsky, C., Rebar, R., Reindollar, R., Shannon, C. N., Steiner, A., Stovall, D., Tanrikut, C., Taylor, H., & Yauger, B. (2020). Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertility and Sterility*, *114*(6), 1151–1157. <https://doi.org/10.1016/j.fertnstert.2020.09.134>
- Poggio, F., Lambertini, M., Bighin, C., Conte, B., Blondeaux, E., D'Alonzo, A., Dellepiane, C., Boccardo, F., & Del Mastro, L. (2018). Management of young women with early breast cancer. *ESMO Open*, *3*, e000458. <https://doi.org/10.1136/esmoopen-2018-000458>
- Purvis, T. E. (2015). Assisted reproduction in Indonesia: policy reform in an Islamic culture and developing nation. *Reproductive BioMedicine Online*, *31*(5), 697–705. <https://doi.org/10.1016/j.rbmo.2015.07.008>
- Puttabyatappa, M., & Padmanabhan, V. (2018). Developmental Programming of Ovarian Functions and Dysfunctions. In *Vitamins and Hormones* (Vol. 107). <https://doi.org/10.1016/bs.vh.2018.01.017>
- Ralhan, R., & Kaur, J. (2007). Alkylating agents and cancer therapy. *Expert Opinion on Therapeutic Patents*, *17*(9), 1061–1075. <https://doi.org/10.1517/13543776.17.9.1061>
- Robertson, J. F. R., & Blamey, R. W. (2003). The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. *European Journal of Cancer*, *39*(7), 861–869. [https://doi.org/10.1016/S0959-8049\(02\)00810-9](https://doi.org/10.1016/S0959-8049(02)00810-9)
- Rodriguez-Wallberg, K. A., Jiang, Y., Lekberg, T., & Nilsson, H. P. (2023). The Late Effects of Cancer Treatment on Female Fertility and the Current Status of Fertility Preservation—A Narrative Review. *Life*, *13*(5). <https://doi.org/10.3390/life13051195>
- Rodriguez-Wallberg, K. A., Kieler, H., Foukakis, T., Li, J., Gissler, M., Oberg, A. S., Bergh, J., & Lundberg, F. E. (2024). Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths – a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden. *EClinicalMedicine*, *67*, 102335. <https://doi.org/10.1016/j.eclinm.2023.102335>
- Rose, S. R., Schreiber, R. E., Kearney, N. S., Lustig, R. H., Danish, R. K., Burghen, G. A., & Hudson, M. M. (2004). Hypothalamic Dysfunction After Chemotherapy. *Journal of Pediatric Endocrinology and Metabolism*, *17*(1). <https://doi.org/10.1515/JPEM.2004.17.1.55>
- Salai, J. S. M., Abdulqadr, N. J., & Dizaye, K. F. (2016). Menstrual and Hormonal Changes in Breast Cancer Patients Treated By Ad-juvant, Adriamycin and

- Cyclophosphamide Chemotherapy. *Advanced Medical Journal*, 2(1), 14–19. <https://doi.org/10.56056/amj.2016.11>
- Sellami, I., Beau, I., & Sonigo, C. (2023). Chemotherapy and female fertility. *Annales d'Endocrinologie*, 84(3), 382–387. <https://doi.org/10.1016/j.ando.2023.03.013>
- Sevko, A., Sade-Feldman, M., Kanterman, J., Michels, T., Falk, C. S., Umansky, L., Ramacher, M., Kato, M., Schadendorf, D., Baniyash, M., & Umansky, V. (2013). Cyclophosphamide Promotes Chronic Inflammation–Dependent Immunosuppression and Prevents Antitumor Response in Melanoma. *Journal of Investigative Dermatology*, 133(6), 1610–1619. <https://doi.org/10.1038/jid.2012.444>
- Shien, T., & Iwata, H. (2020). Adjuvant and neoadjuvant therapy for breast cancer. *Japanese Journal of Clinical Oncology*, 50(3), 225–229. <https://doi.org/10.1093/jjco/hyz213>
- Shrikhande, L., Shrikhande, B., & Shrikhande, A. (2020). AMH and Its Clinical Implications. *The Journal of Obstetrics and Gynecology of India*, 70(5), 337–341. <https://doi.org/10.1007/s13224-020-01362-0>
- Silva, C., Caramelo, O., Almeida-Santos, T., & Ribeiro Rama, A. C. (2016). Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. *Human Reproduction*, 31(12), 2737–2749. <https://doi.org/10.1093/humrep/dew224>
- Sinn, H.-P., & Kreipe, H. (2013). A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. *Breast Care*, 8(2), 149–154. <https://doi.org/10.1159/000350774>
- Su, H. I., Flatt, S. W., Natarajan, L., DeMichele, A., & Steiner, A. Z. (2013). Impact of breast cancer on anti-mullerian hormone levels in young women. *Breast Cancer Research and Treatment*, 137(2), 571–577. <https://doi.org/10.1007/s10549-012-2361-5>
- Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017). Risk Factors and Preventions of Breast Cancer. *International Journal of Biological Sciences*, 13, 1387–1397. <https://doi.org/10.7150/ijbs.21635>
- Swain, S. M., Shastry, M., & Hamilton, E. (2023). Targeting HER2-positive breast cancer: advances and future directions. *Nature Reviews Drug Discovery*, 22(2), 101–126. <https://doi.org/10.1038/s41573-022-00579-0>
- Thomas-Teinturier, C., Allodji, R. S., Svetlova, E., Frey, M.-A., Oberlin, O., Millischer, A.-E., Epelboin, S., Decanter, C., Pacquement, H., Tabone, M.-D., Sudour-Bonnange, H., Baruchel, A., Lahlou, N., & De Vathaire, F. (2015). Ovarian reserve after treatment with alkylating agents during childhood. *Human Reproduction*, 30(6), 1437–1446. <https://doi.org/10.1093/humrep/dev060>
- Tim Registrasi Kanker RSUP Dr. Sardjito/FK-KMK UGM. (2022). Laporan Registrasi Kanker Berbasis Rumah Sakit Maret periode Maret 2022. In *Yogyakarta*. <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/>

- Turner, N. H., Partridge, A., Sanna, G., Di Leo, A., & Biganzoli, L. (2013). Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. *Annals of Oncology*, 24(9), 2224–2235. <https://doi.org/10.1093/annonc/mdt196>
- Valsamakis, G., Valtetsiotis, K., Charmandari, E., Lambrinoudaki, I., & Vlahos, N. F. (2022). GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation. *International Journal of Molecular Sciences*, 23(4), 2287. <https://doi.org/10.3390/ijms23042287>
- van Iersel, L., & Chemaitilly, W. (2021). *Hypothalamic-Pituitary Dysfunctions Other Than Growth Hormone Deficiency in Cancer Survivors* (pp. 36–46). <https://doi.org/10.1159/000513806>
- Vural, B., Cakiroglu, Y., Vural, F., & Filiz, S. (2014). Hormonal and functional biomarkers in ovarian response. *Archives of Gynecology and Obstetrics*, 289(6), 1355–1361. <https://doi.org/10.1007/s00404-013-3132-1>
- Warren, J. G., Fallon, V. M., Goodwin, L., Gage, S. H., & Rose, A. K. (2021). Menstrual Cycle Phase, Hormonal Contraception, and Alcohol Consumption in Premenopausal Females: A Systematic Review. *Frontiers in Global Women's Health*, 2. <https://doi.org/10.3389/fgwh.2021.745263>
- Weenen, C., Laven, J. S. E., von Bergh, A. R. M., Cranfield, M., Groome, N. P., Visser, J. A., Kramer, P., Fauser, B. C. J. M., & Themmen, A. P. N. (2004). Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. *Molecular Human Reproduction*, 10(2), 77–83. <https://doi.org/10.1093/molehr/gah015>
- Wu, C., Wu, T., Chen, D., Wei, S., Tang, W., Xue, L., Xiong, J., Huang, Y., Guo, Y., Chen, Y., Wu, M., & Wang, S. (2022). The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence. *Frontiers in Endocrinology*, 13. <https://doi.org/10.3389/fendo.2022.1025018>
- Xu, H., Zhang, M., Zhang, H., Alpadi, K., Wang, L., Li, R., & Qiao, J. (2021). Clinical Applications of Serum Anti-Müllerian Hormone Measurements in Both Males and Females: An Update. *The Innovation*, 2(1), 100091. <https://doi.org/10.1016/j.xinn.2021.100091>
- Zong, X., Yu, Y., Chen, W., Zong, W., Yang, H., & Chen, X. (2022). Ovarian reserve in premenopausal women with breast cancer. *The Breast*, 64. <https://doi.org/10.1016/j.breast.2022.05.009>
- Zong, X., Yu, Y., Yang, H., Chen, W., Ding, X., Liu, S., Li, X., Chen, X., Jiang, C., Xia, X., Huang, R., Zhu, M., Hu, J., & Liang, C. (2022). Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China. *JAMA Oncology*, 8(2), 252. <https://doi.org/10.1001/jamaoncol.2021.6214>